Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. - Wikidata - awgldk - TriplyDB

Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs.

Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs.

http://www.wikidata.org/entity/Q35132201

about

Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini Review The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases.Current perspectives in NSAID-induced gastropathy Non-microbial approach for Helicobacter pylori as faster track to prevent gastric cancer than simple eradication 15-Lipoxygenase metabolites of α-linolenic acid, [13-(S)-HPOTrE and 13-(S)-HOTrE], mediate anti-inflammatory effects by inactivating NLRP3 inflammasome.Potential Antifungal Targets against a Candida Biofilm Based on an Enzyme in the Arachidonic Acid Cascade-A Review The effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosa Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond 5-lipoxygenase antagonist therapy: a new approach towards targeted cancer chemotherapy Alleviating Promotion of Inflammation and Cancer Induced by Nonsteroidal Anti-Inflammatory Drugs Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection.Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease 5-Lipoxygenase inhibitors attenuate TNF-α-induced inflammation in human synovial fibroblasts Anti-inflammatory effects of Polygonum minus (Huds) extract (Lineminus™) in in-vitro enzyme assays and carrageenan induced paw edema.Investigational pharmacology for low back pain.ω-3 polyunsaturated fatty acids-derived lipid metabolites on angiogenesis, inflammation and cancer Flavocoxid inhibits phospholipase A2, peroxidase moieties of the cyclooxygenases (COX), and 5-lipoxygenase, modifies COX-2 gene expression, and acts as an antioxidant Inhibition of aldose reductase prevents endotoxin-induced inflammation by regulating the arachidonic acid pathway in murine macrophages.Challenges and opportunities in animal drug development: a regulatory perspective.Mechanisms of gastroprotection of methanol extract of Melastoma malabathricum leaves.The effect of Zingiber officinale R. rhizomes (ginger) on plasma pro-inflammatory cytokine levels in well-trained male endurance runners.Synthesis and Biological Evaluation of New Phthalazinone Derivatives as Anti-Inflammatory and Anti-Proliferative Agents.Nitroxide derivatives of non-steroidal anti-inflammatory drugs exert anti-inflammatory and superoxide dismutase scavenging properties in A459 cells.Anti-inflammatory trends of new benzimidazole derivatives.The Gastroprotective Role of Acanthus ilicifolius - A Study to Unravel the Underlying Mechanism of Anti-Ulcer Activity.Anti-inflammatory and cytotoxic activities of Bursera copallifera.Pathophysiology and management of surgical and chronic oral pain in dogs and cats.Perivascular fat: innocent bystander or active player in vascular disease?Activity and potential role of licofelone in the management of osteoarthritis.Synthesis and quantitative structure-activity relationship study of substituted imidazophosphor ester based tetrazolo[1,5-b]pyridazines as antinociceptive/anti-inflammatory agents.A broad-spectrum lipidomics screen of antiinflammatory drug combinations in human blood.Effect of 5-LOX/COX-2 common inhibitor DHDMBF30 on pancreatic cancer cell Capan2 Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages.Herbal medicinal products target defined biochemical and molecular mediators of inflammatory autoimmune arthritis.5-Lipoxygenase metabolic contributions to NSAID-induced organ toxicity.Prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs), more than meets the eye: a critical review.Flavocoxid, a nutraceutical approach to blunt inflammatory conditions.Recent developments in chimeric NSAIDs as safer anti-inflammatory agents.Management of NSAID-associated peptic ulcer disease.Pyridazinone: an attractive lead for anti-inflammatory and analgesic drug discovery.

P2860

Q24634894-4D540B15-EDDB-4017-A84B-303F695A530C Q24812406-2802A838-F58F-4BEB-B3C5-EB2F0D268F63 Q26827673-3C780849-4671-402C-820B-933AD978ED88 Q27006833-41A0DCA7-2752-4786-A830-BA425A1AD3B2 Q27316915-7846F754-4157-4DA2-97F8-30A416EC6F3D Q28077611-2FD92483-7C1C-4C20-B8EA-1854F9DEDC74 Q28194351-A8E88162-C457-4419-90C0-0E18735E2399 Q28210656-4DA4FCDB-3978-4EEE-BEFD-72366F8FF3A6 Q28292415-A09FEF01-BEDD-4971-B6C4-0283400E1E39 Q30234292-23609B70-FD61-4DBD-B458-426AF7F4A32E Q33595066-B8B41E2B-C0CD-42FB-8F68-69DC27C8AAF8 Q33923169-C2DF41D5-ECEF-4D7E-9BE9-2BAC7E739AEF Q34208803-39C4A09C-E220-45D4-A91A-AEEC51578668 Q34274400-28B0D4C9-558D-4A9F-8F69-E54661AAF084 Q34418362-52A53259-B1C0-4759-91AA-C8B8E7D00AE8 Q34428959-E4E65BD4-CFC4-4913-A054-24DBC8C124F1 Q35098944-55B7E185-5211-4C47-98A0-7BD46EDC6F14 Q35281290-87D6533F-BA9A-42AE-BCDA-E2F24C65EFAD Q35560009-9BCDCBD9-A5EF-4D6D-BA0C-7E80CD482A37 Q35619063-0ED18BDA-2EAB-46D5-9110-682E4BE26A1B Q35631900-E71607AE-0037-4274-9E03-4B0A604AEF9A Q35883512-52B255AD-B7AD-421E-A0A9-BF8CD5D8F161 Q35940349-304BFF3E-56CF-41B1-940F-7A131908617E Q36139722-39922724-2C23-40F7-9287-D02D3B6E420E Q36248965-3BA14421-279D-4711-8D87-273F7D689F97 Q36300768-9F333CD8-EAC9-4235-AAC6-7F738B9A2557 Q36485877-C6F64BA8-305B-4220-9304-15BD804E06FA Q36902772-7B6770DC-8D6D-4022-AEA4-22068A9428F6 Q37017276-34129DFB-AB41-42C4-A3E3-3FE3C8B1C8E4 Q37185968-92DAF2DE-54F5-461B-B569-8CC521878CDE Q37187622-4728C478-30E6-44D2-A36C-A87F40EF8F9D Q37256004-48AD0EFE-D42C-40D1-A14F-75AB364AC051 Q37395300-B746335D-0295-4235-B080-91B8C59092F0 Q37813237-1CA1B899-DA60-4859-8F0D-194EE4F1AA0F Q37986694-154CF1F3-F690-4504-B14D-96214C37E0C8 Q38068081-A5031593-3C64-4F79-AB29-E41E21532B0F Q38253044-3E0D3C02-3E02-4BD1-906E-C952B58B52AE Q38260626-F989AC56-8339-4526-AFF2-DE41E8DD1D32 Q38699305-D7CE6214-CBC2-449D-9C4F-D765F1EFEC81 Q38783636-BBECCE77-D687-4112-A822-073CD7CBBF11

P2860

Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs.

http://www.wikidata.org/entity/Q35132201

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Therapeutic role of dual inhib ...... oidal anti-inflammatory drugs.

@ast

Therapeutic role of dual inhib ...... oidal anti-inflammatory drugs.

@en

type

label

Therapeutic role of dual inhib ...... oidal anti-inflammatory drugs.

@ast

Therapeutic role of dual inhib ...... oidal anti-inflammatory drugs.

@en

prefLabel

Therapeutic role of dual inhib ...... oidal anti-inflammatory drugs.

@ast

Therapeutic role of dual inhib ...... oidal anti-inflammatory drugs.

@en

P1433

Q35132201-E3A2AE1D-9B03-4F09-8D0B-09F7A0BC0EA5

P1476

Q35132201-C37469EC-06B5-4E35-A97B-EC55DDA77316

P2093

Q35132201-483968E5-25C0-4984-9124-B54FF07E43D1

Q35132201-4EE8B25E-55A8-499F-9F99-16F1CA6B3F3D

Q35132201-E9BB17CE-B474-4E2C-960D-7E127C721437

P2860

Q35132201-032B7780-6A5D-4103-A2B5-86D2CD2D6360

Q35132201-0416FE22-CD2C-4024-AD8F-4D30E374622E

Q35132201-06507251-9776-41C2-A9A7-68FF185AD791

Q35132201-0755F82F-965A-4297-9742-BFB6D9156DAF

Q35132201-0CAD1D93-A24A-4E61-A64C-E142A9861918

Q35132201-0F6CC29B-6BFC-4BE3-9DF6-03638AEE6851

Q35132201-10ED9A33-94F1-47FF-BAB1-E9C09A92F937

Q35132201-152DC15A-067D-4BF5-9CFD-96CF2C0EB090

Q35132201-1600BD41-BF95-4591-9079-E5CD90D8A742

Q35132201-191231B5-2DAC-4D4D-AE4F-9D0CF13B4E13

P304

Q35132201-972B4F14-B172-4A7C-990E-4B04684DC3BB

P31

Q35132201-A3EA0864-57C7-44B6-BB22-FCFFCCC4EC23

P356

Q35132201-35EDF7BD-F245-4763-B185-73D78967C2D0

P407

Q35132201-2E2165F9-D1D8-476C-9536-5413BA9EEB6C

P433

Q35132201-BFE0FF67-CE09-453A-9AD3-5DB0973C008D

P478

Q35132201-A6491D7B-04CB-4AA4-A3DD-852436A568ED

P50

Q35132201-AFD148FA-D48C-4B4C-862C-642217BAEC98

P577

Q35132201-684F294A-2AD8-4E33-BB6A-A718B3B4EA19

P698

Q35132201-4060FF5D-A7FC-40D0-9076-03888A46D36C

P932

Q35132201-C8A6B367-79EB-42A8-9BAC-990549FB8ECB

P356

P1433

Annals of the Rheumatic Diseases

P1476

Therapeutic role of dual inhib ...... roidal anti-inflammatory drugs

@en

P2093

D Lajeunesse

http://www.w3.org/2001/XMLSchema#string

J Martel-Pelletier

http://www.w3.org/2001/XMLSchema#string

J-P Pelletier

http://www.w3.org/2001/XMLSchema#string

P2860

Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis

Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release

Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors

Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity?

The molecular biology and regulation of 5-lipoxygenase

Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways

Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2

Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

Cyclooxygenase 2 and the kidney.

P304

501-509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.62.6.501

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12759283

http://www.w3.org/2001/XMLSchema#string

P932

1754580

http://www.w3.org/2001/XMLSchema#string